Skip to main content

Table 1 Characteristics of patients

From: A phase II clinical trial to investigate the effect of pioglitazone on 18F-FDG uptake in malignant lesions

Characteristics

Age (mean ± SD, year)

64.0 ± 11.8

   

Sex (M:F)

30:13

    

Type of malignancy

Responder (lesion/patient)

Non-responder (lesion/patient)

Benign lesion

Responder (lesion/patient)

Non-responder (lesion/patient)

Hepatobiliary and pancreatic cancer

18/9

6/4

Mediastinal lymph node

9/7

4/3

Hepatocellular carcinoma

7/6

5/4

Pneumonia

1/1

Colorectal cancer

7/5

2/1

Rib fracture

1/1

Gastric cancer

4/4

7/4

Liver cyst

1/1

Esophageal cancer

3/1

2/1

   

Renal cell carcinoma

2/1

   

Duodenal GIST

1/1

   

Lung cancer

1/1